Welcome to our dedicated page for Aytu Biopharma news (Ticker: AYTU), a resource for investors and traders seeking the latest updates and insights on Aytu Biopharma stock.
Aytu BioPharma, Inc. (AYTU) is a Nasdaq-listed pharmaceutical company focused on advancing medicines for complex central nervous system diseases, with an emphasis on major depressive disorder (MDD) and attention deficit-hyperactivity disorder (ADHD). Its news flow reflects this focus, highlighting commercial progress, clinical positioning and corporate developments around its prescription portfolio.
A central theme in Aytu’s recent news is EXXUA (gepirone) extended-release tablets, a novel oral selective serotonin 5HT1a receptor agonist indicated for the treatment of MDD in adults. Company announcements have covered the commercial availability of EXXUA in the United States, its status as the first and only 5HT1a agonist approved by the U.S. Food and Drug Administration for MDD, and integration of EXXUA distribution into Aytu’s RxConnect patient access platform.
Investors following AYTU news will also see updates on the company’s ADHD Portfolio and Pediatric Portfolio performance, including revenue trends and commentary from management in quarterly operational and financial results. Aytu’s press releases discuss net revenue by portfolio, gross profit, adjusted EBITDA and investments related to the EXXUA launch.
In addition, Aytu regularly announces participation in investor conferences, healthcare summits and dedicated Investor Day events. These items often feature presentations by senior management and key opinion leaders in psychiatry, focusing on EXXUA’s clinical profile, market opportunity and the company’s broader CNS strategy. For investors and observers, the AYTU news page provides a centralized view of product launches, patent developments, financing updates and ongoing investor outreach activities.
Aytu BioPharma (NASDAQ:AYTU) will report its financial results for Q4 and fiscal year ending June 30, 2022, after market close on September 27, 2022. A conference call is scheduled for the same day at 4:30 pm ET to discuss the results. Aytu's product portfolio focuses on novel therapeutics for rare pediatric disorders, including Adzenys XR-ODT and Cotempla XR-ODT for ADHD treatment. The company is also advancing therapies like AR101 for Vascular Ehlers-Danlos Syndrome, which has received multiple designations from the FDA and the European Commission.
Aytu BioPharma announced the addition of its fourth patent for AR101/Enzastaurin, enhancing its intellectual property portfolio for treating Vascular Ehlers-Danlos Syndrome (VEDS). Licensed from Johns Hopkins University, this patent expands the understanding of VEDS pathophysiology, with an expiry date of September 2041. The company plans to start the PREVEnt Trial for AR101 in early 2023, aiming to treat COL3A1-confirmed VEDS, a rare disorder with no approved therapies. Aytu holds Orphan Drug and Fast Track designations for AR101, which targets significant medical needs in VEDS.
Aytu BioPharma (NASDAQ:AYTU), a pharmaceutical company focused on rare pediatric-onset disorders, is set to participate in two upcoming investor conferences. The H.C. Wainwright 24th Annual Global Investment Conference will feature an on-demand presentation from September 12, 2022. Additionally, the Lytham Partners Fall 2022 Investor Conference offers a recorded fireside chat starting September 28, 2022. Both events will include opportunities for 1x1 virtual meetings. These presentations showcase Aytu's commitment to innovative therapeutics.
Aytu BioPharma (NASDAQ:AYTU) announced the issuance of U.S. Patent No. 11,273,148 for AR101 (enzastaurin), marking a significant milestone in its intellectual property portfolio. This patent covers methods for treating inherited aortic aneurysms and related conditions, including Vascular Ehlers-Danlos Syndrome (VEDS), with an expiry date in August 2038. The company aims to initiate the PREVEnt Trial for AR101 in VEDS, expecting to dose the first patient by early 2023. AR101 has received Orphan Drug and Fast Track designations from the FDA, highlighting its potential in addressing unmet medical needs.
Aytu BioPharma (NASDAQ:AYTU) closed its underwritten public offering, raising $10.0 million through the sale of 21,505,814 shares of common stock and 1,750,000 pre-funded warrants. The offering included Common Warrants for an additional 23,255,814 shares. The funds will be used to advance pipeline assets, including the PREVEnt Trial for AR101, aimed at treating vascular Ehlers-Danlos Syndrome, and for general corporate purposes. Total shares outstanding after the offering rose to 62,432,727.
Aytu BioPharma will participate in the Canaccord Genuity 42nd Annual Growth Conference from August 8-11, 2022, in Boston, MA. CEO Josh Disbrow and CFO Mark Oki will conduct one-on-one meetings on August 9 and 10, with a corporate overview presentation scheduled for 4:00 p.m. ET on August 10. A live webcast of the presentation will be available on the company's website, along with an online replay.
Aytu BioPharma focuses on developing therapeutics for rare pediatric disorders, including Vascular Ehlers-Danlos Syndrome.
Aytu BioPharma (NASDAQ:AYTU) announced the launch of the Phase 3 PREVEnt trial for enzastaurin (AR101), targeting patients with Vascular Ehlers-Danlos Syndrome (VEDS), a rare genetic condition. The trial, with over 30 sites across the US and Europe, aims to evaluate enzastaurin's efficacy in reducing serious arterial events. The FDA has granted a Safe to Proceed Letter, and approvals have been obtained in several European countries. Patient recruitment is underway, with the goal of dosing the first patient by early 2023.
Aytu BioPharma announces the appointment of Vivian Liu to its board of directors, effective July 1, 2022. Liu, with extensive experience in biotechnology, is expected to bolster the company's focus on growth, particularly in developing therapeutics for rare diseases. CEO Josh Disbrow expressed confidence in Liu's ability to drive the company's strategic plans. Currently, Liu is Head of Corporate Affairs for PREMIA Holdings and has held leadership roles in several pharmaceutical companies. Aytu is focused on enhancing its therapeutic pipeline and expanding commercial operations.
Aytu BioPharma (NASDAQ:AYTU) will participate in the Lytham Partners Summer 2022 Investor Conference on June 21-22, 2022. Aytu's webcast presentation is scheduled for 9:00 am ET on June 21 and will be available for replay on the company’s website. Management will also engage in virtual one-on-one meetings during the conference. Aytu focuses on developing novel therapeutics, including treatments for rare pediatric disorders and conditions like ADHD. Their pipeline includes AR101, aimed at Vascular Ehlers-Danlos Syndrome, which has received FDA Orphan Drug designation.
Aytu BioPharma reported a 79% increase in quarterly net revenue, reaching $24.2 million, the highest in its history. Prescription revenue surged 170% year-over-year to $13.9 million. The company is focusing on enhancing financial performance, with plans to improve gross margins through manufacturing efficiencies. However, it recorded a net loss of $53.1 million primarily due to a $45.2 million impairment related to goodwill from the Neos acquisition. Cash reserves stand at $27.6 million as of March 31, 2022.